Guggenheim adjusted its price target on shares of AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), increasing it to GBP13,100 from ...

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country ...

In the latest trading session, Astrazeneca (AZN ... Elsewhere, the Dow saw an upswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.06%. The the stock of pharmaceutical has fallen ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world.

The most recent trading session ended with Astrazeneca (AZN ... Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.49%. The pharmaceutical's stock has dropped by 1.01% ...

AstraZeneca (AZN) changes key management roles in China as the company emerges from several scandals involving its executives ...

David Jagielski (AstraZeneca): If you're buying a top growth stock, you often have to pay a hefty premium for it, but that isn't the case with AstraZeneca. Despite having a wealth of products in ...

Leading vaccine makers like Eli Lilly and Co. (NYSE: LLY), Pfizer Inc. (NYSE: PFE), and AstraZeneca plc (NASDAQ: AZN) may have faded from the spotlight since the peak of the COVID-19 pandemic ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced ...

Investors in AstraZeneca plc (Symbol: AZN) saw new options begin trading today, for the March 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo (DSNKY) and AstraZeneca (AZN).